These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11240034)

  • 1. Human IgM anti-GM1 autoantibodies modulate intracellular calcium homeostasis in neuroblastoma cells.
    Quattrini A; Lorenzetti I; Sciorati C; Corbo M; Previtali SC; Feltri ML; Canal N; Wrabetz L; Nemni R; Clementi E
    J Neuroimmunol; 2001 Mar; 114(1-2):213-9. PubMed ID: 11240034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous ganglioside GM1 modulates L-type calcium channel activity in N18 neuroblastoma cells.
    Carlson RO; Masco D; Brooker G; Spiegel S
    J Neurosci; 1994 Apr; 14(4):2272-81. PubMed ID: 7512636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes.
    Niebroj-Dobosz I; Janik P; Kwieciński H
    Eur J Neurol; 2004 Jan; 11(1):13-6. PubMed ID: 14692882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.
    Pestronk A; Choksi R
    Neurology; 1997 Nov; 49(5):1289-92. PubMed ID: 9371910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of cholera toxin B subunit-induced Ca(2+) influx in neuroblastoma cells: evidence for a voltage-independent GM1 ganglioside-associated Ca(2+) channel.
    Fang Y; Xie X; Ledeen RW; Wu G
    J Neurosci Res; 2002 Sep; 69(5):669-80. PubMed ID: 12210833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line.
    Cavanna B; Carpo M; Pedotti R; Scarpini E; Meucci N; Allaria S; Scarlato G; Nobile-Orazio E
    J Neuroimmunol; 1999 Feb; 94(1-2):157-64. PubMed ID: 10376949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELISA-type titertray assay of IgM anti-GM1 autoantibodies.
    Bech E; Jakobsen J; Orntoft TF
    Clin Chem; 1994 Jul; 40(7 Pt 1):1331-4. PubMed ID: 8013109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of anti-GM1 IgM antibodies.
    Nobile-Orazio E; Carpo M; Scarlato G
    Acta Neurol (Napoli); 1991 Dec; 13(6):514-9. PubMed ID: 1805551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of testing for anti-GM1 antibodies.
    McCombe PA; Wilson R; Prentice RL
    J Clin Neurosci; 2000 May; 7(3):209-12. PubMed ID: 10833617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibodies to GM1 ganglioside in motor neuron disease--in comparison with demyelinating neuropathy].
    Irie S; Saito T; Ogino M; Ito H; Kowa H
    Rinsho Shinkeigaku; 1992 Oct; 32(10):1075-80. PubMed ID: 1297550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy.
    Yuki N; Watanabe H; Nakajima T; Späth PJ
    J Neurol Neurosurg Psychiatry; 2011 Jan; 82(1):87-91. PubMed ID: 20667861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-GM1 and anti-GD1a antibodies in patients with motor neuron disease.
    Voumvourakis C; Rombos A; Konstantoulakis MM; Segditsa I; Papageorgiou C
    Acta Neurol Scand; 1992 Dec; 86(6):599-602. PubMed ID: 1481647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls.
    Uetz-von Allmen E; Sturzenegger M; Rieben R; Rihs F; Frauenfelder A; Nydegger UE
    Eur Neurol; 1998; 39(2):103-10. PubMed ID: 9520071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-fucosyl-GM1 ganglioside IgG and IgM autoantibodies in human serum: no link to pathology.
    Adler G; Pacuszka T; Strugalska M; Targońska I; Panasiewicz M; Lewartowska A
    Immunol Lett; 1996 Sep; 52(2-3):89-93. PubMed ID: 8905401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
    Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
    J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides.
    Wirguin I; Suturkova-Milosevic L; Della-Latta P; Fisher T; Brown RH; Latov N
    Ann Neurol; 1994 Jun; 35(6):698-703. PubMed ID: 8210226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone.
    Pestronk A; Choksi R; Blume G; Lopate G
    Neurology; 1997 Apr; 48(4):1104-6. PubMed ID: 9109910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning of human anti-GM1 antibodies from motor neuropathy patients.
    Willison HJ; Paterson G; Kennedy PG; Veitch J
    Ann Neurol; 1994 Apr; 35(4):471-8. PubMed ID: 8154875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of transmembrane signaling by ganglioside GM1: interaction of anti-GM1 with Neuro2a cells.
    Ravichandra B; Joshi PG
    J Neurochem; 1999 Aug; 73(2):557-67. PubMed ID: 10428051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower motor neuron syndrome associated with IgG anti-GM1 antibodies revisited.
    Yuki N; Yanaka C; Sudo M; Funakoshi M; Ishida H; Mori M; Kanda F; Hirata K
    J Neuroimmunol; 2014 Jul; 272(1-2):62-6. PubMed ID: 24841627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.